drugset / Trial / NCT00002800
Chemotherapy in Treating Patients With Newly Diagnosed Acute or Chronic Myelogenous Leukemia or Myelodysplastic Syndrome
Phase 2
Completed
60 enrolled
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI) · collab
Treatment
Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining more than one drug may kill more cancer cells. PURPOSE: Phase II trial to study the effectiveness of high-dose cytarabine plus idarubicin in treating patients with newly diagnosed acute or chronic myelogenous leukemia or myelodysplastic syndrome.
Timeline
- Start
- 1996-07
- Primary completion
- 2003-03
- Completion
- 2003-03
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Cytarabine | Small molecule | — | — |
| Subject | Etoposide | Small molecule | — | — |
| Subject | Idarubicin | Small molecule | — | — |
| Subject | lintuzumab | Monoclonal antibody | — | — |
| Background | filgrastim | Protein / enzyme biologic | — | — |